The Global Infectious Disease Diagnostics market is forecast to reach USD 28.03 Billion by 2027, according to a new report by Reports and Data. Immediate diagnosis of infectious disease is the present need of the time due to evolving pathogens and increasing the occurrence rate of hospital-acquired infections. Government of various nations has been emphasizing on rapid diagnosis of infectious disease as a strategic priority like in the U.S. The global COVID-19 pandemic is another mentionable crucial factor that is boosting the demand for laboratory-based molecular testing capacity and reagents.

The COVID-19 Impact: One of the major impacts of COVID-19 on the market has been elevated demand for point-of-care immunodiagnostic tests. The development of these easy-to-use and rapid devices to support testing outside of laboratory settings has been a response of diagnostic test manufacturers to shortages of laboratory-based molecular testing capacity. These test kits are developed by manufacturers based either on detection, in serum or blood of antibodies caused due to the infection or identification of proteins from the coronavirus in respiratory samples. WHO supports the use of these point-of-care immunodiagnostic tests in research settings.    

Another mentionable impact of the pandemic on the market has been the emphasis on RD activities. Various market players have been working on developing commercial and in-house assays that identify the COVID-19 virus. It would also contribute to the growing demand for molecular microfluidics diagnostics. Herein, technological advancements, development of microfluidic-based solutions by various market players, and scope to automate complex sample preparations on microchips and reliability associated with it in detecting pathogens would result in its surging demand during this epidemic. It would also boost the demand for respiratory testing. Some industry players have also been emphasizing on developing respiratory tests for coronavirus. These respiratory tests for COVID-19 would also be applicable for other respiratory pathogens like influenza A and B. Thus; it would result in ascertaining stable growth of the market. 

However, one of the mentionable challenges for the growth of the market players amidst this epidemic is supply chain management. As an instance, in China when the pandemic reached the zenith, the transportation was to a halt that resulted in breaking the supply chain. The main reason for such disruption is not because companies are not manufacturing, but it was because the mobility of comments from one part of the nation to another was becoming a challenge. Thus, such disruption in the supply chain may hinder the growth of the market.               

Request a sample report of Infectious Disease Diagnostics Market @ https://www.reportsanddata.com/download-free-sample/2956

Further key findings from the report suggest

• In context to Product Type, the Consumables segment is projected to witness a considerable growth rate of 6.3% during the forecast period. The elevating demand for assays and reagents because of rising demand for IDD tests contributes to the growth rate witnessed by this segment. The increasing occurrence rate of infectious diseases like COVID-19 and growing geriatric population is resulting in increasing demand for IDD tests. The epidemic is resulting in the development of various commercial and in-house assays to detect the virus, which is also contributing to the growth rate witnessed by this segment.
• In regards to Technology, the Molecular diagnostic technique segment is projected to witness a faster growth rate during the forecast period. The growth rate witnessed by the Molecular diagnostic technique is attributed to increasing demand for Polymerase Chain Reaction and Isothermal Nucleic Acid Amplification Test. Furthermore, development of assays using this technology like molecular assays, the use of which is supported by WHO, is also contributing to the growth rate witnessed by this segment.
• In regards to Disease Type, the Hepatitis segment occupied the largest market share of more than 20.0% in 2019. The market share held by the Hepatitis diagnostics is attributed to elevating the adoption of developed technologies for hepatitis B diagnosis and high occurrence rate of the condition, particularly among individuals below forty years, which contributes to the market share held by this segment.   
• Abbott has been expanding its accessibility to COVID-19 tests by elevating its production and shipping to customers. As of April 2020, the company has been manufacturing 50,000 tests per day.
• In April 2020, E25Bio has developed a rapid antigen test for COVID-19. This test is capable of conducting the COVID-19 test in 15 minutes. Currently, the test is awaiting FDA clearance.
• Key participants include Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Biomérieux SA, Diasorin, Danaher Corporation, Meridian Bioscience, Luminex, Roche Diagnostics, and Siemens AG.
• Deals Landscape
• In February 2020, Bio-Rad Laboratories acquired Exact Diagnostics of Fort Worth. With the help of this acquisition the company gained accessibility to catalog of molecular quality control products in microbiology, virology, respiratory, vector-borne, transplant and sexually transmitted infections.
• In January 2018, Siemens had completed the acquisition of Fast Track Diagnostics. With the help of this acquisition, Siemens can expand its assays and syndromic panels and enhance its quality of care delivery.    

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/2956

For the purpose of this report, Reports and Data have segmented the Infectious Disease Diagnostics market on the basis of Product Type, Technology, Disease Type, End-user, and region:

Product Type Outlook (Revenue, USD Billion; 2017-2027)

• Consumables
• Instruments analyzers
• Software services

Technology Outlook (Revenue, USD Billion; 2017-2027)

• Traditional diagnostic technique
• Molecular diagnostic technique

Disease Type Outlook (Revenue, USD Billion; 2017-2027)

• Hepatitis
• Hospital-Acquired Infections (HAIS)
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
• Influenza
• Human Papillomavirus
• Others

End-user Outlook (Revenue, USD Billion; 2017-2027)

• Reference Laboratories
• Hospital/Clinical Laboratories
• Academic/Research Institutes
• Physician Offices
• Others

Regional Outlook (Revenue, USD Billion; 2017-2027)

• North America
• U.S
• Europe
• U.K
• France
• Asia Pacific
• China
• India
• Japan
• MEA
• Latin America
• Brazil

Request customization of the report @

https://www.reportsanddata.com/request-customization-form/2956

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs